<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637037</url>
  </required_header>
  <id_info>
    <org_study_id>D1691C00008</org_study_id>
    <nct_id>NCT02637037</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects</brief_title>
  <official_title>A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants in Healthy Subjects Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study to compare 2 fixed-dose combination tablets of
      dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under
      fasting and fed conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, 2-part, open-label, randomized, 4-period, 4-treatment, crossover study in
      healthy subjects (males and females of non-childbearing potential)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2015</start_date>
  <completion_date type="Actual">April 7, 2016</completion_date>
  <primary_completion_date type="Actual">April 7, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (t Max)</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]</measure>
    <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
    <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Bioequivalence</condition>
  <condition>Fixed Dose Combination Tablets</condition>
  <condition>Healthy Male and Female Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment H</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)</intervention_name>
    <description>single fixed-combination dose tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)</intervention_name>
    <description>single fixed-dose combination tablets</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)</intervention_name>
    <description>single fixed-dose combination tablets</description>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)</intervention_name>
    <description>single fixed-dose combination tablets</description>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_label>Treatment H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures

          2. Healthy male and female subjects aged 18 - 55 years with suitable veins for
             cannulation or repeated venipuncture

          3. Females must have a negative serum pregnancy test at screening and on admission to the
             unit, must not be lactating and must be of non-childbearing potential, confirmed at
             screening by fulfilling 1 of the following criteria:

               -  Post-menopausal defined as amenorrhea for at least 12 months or more following
                  cessation of all exogenous hormonal treatments and follicle-stimulating hormone
                  (FSH) levels in the post-menopausal range

               -  Documentation of irreversible surgical sterilization by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy, but not tubal ligation

          4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg inclusive at screening

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          2. History or presence of gastrointestinal, hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the first administration of investigational medicinal product

          4. Any clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis results, as judged by the investigator

          5. Any clinically significant abnormal findings in vital signs, as judged by the
             investigator

          6. Any clinically significant abnormalities on 12-lead ECG as judged by the investigator

          7. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV) antibody

          8. Known or suspected history of drug abuse, as judged by the investigator

          9. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 3 months of the first administration of IMP in this
             study. The period of exclusion begins 3 months after the final dose.

         10. Plasma donation within 1 month of screening or any blood donation/loss more than 500
             mL during the 3 months prior to screening

         11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the investigator or history of hypersensitivity to drugs with a similar
             chemical structure or class to dapagliflozin/metformin XR.

         12. Current smokers or those who have smoked or used nicotine products within the 3 months
             prior to screening

         13. Positive screen for drugs of abuse, cotinine or alcohol at screening or on each
             admission to the study center

         14. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks
             prior to the first administration of IMP

         15. Use of any prescribed or non-prescribed medication including antacids, analgesics
             (other than paracetamol/acetaminophen), herbal remedies, vitamins and minerals during
             the 2 weeks prior to the first administration of IMP or longer if the medication has a
             long half-life

         16. Known or suspected history of alcohol abuse or excessive intake of alcohol as judged
             by the investigator

         17. Involvement of any AstraZeneca or study site employee or their close relatives

         18. Judgment by the investigator that the subject should not participate in the study if
             they have any ongoing or recent (i.e., during the screening period) minor medical
             complaints that may interfere with the interpretation of study data or are considered
             unlikely to comply with study procedures, restrictions and requirements

         19. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,
             trusteeship, or committed to an institution by governmental or juridical order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MDCM, M.Sc, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>March 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dapagliflozin/metformin XR 5/500 mg</keyword>
  <keyword>dapagliflozin/metformin XR10/1000 mg</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>fixed dose combination tablets</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>type 2 Diabetes Mellitus (T2DM)</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at PAREXEL International, Early Phase Clinical Unit Baltimore, United States of America. Subjects were randomized into 4-period, 4-treatment (per study part) crossover (4 sequences containing 4 treatments) in fed and fasted state.</recruitment_details>
      <pre_assignment_details>Sequences 1, 2, 3 and 4 Part 1: ABCD, BADC, ABDC, BACD Part 2: EFGH, FEHG, EFHG, FEGH (A = test, fed; B = reference, fed; C = test, fasted; D = reference, fasted; E = test, fed; F = reference, fed; G = test, fasted; H = reference, fasted) A total of 80 subjects were randomized into the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1</title>
          <description>Sequences 1, 2, 3 and 4- each sequence had 10 subjects; Part 1: ABCD, BADC, ABDC, BACD (A = test, fed; B = reference, fed; C = test, fasted; D = reference, fasted) Part 1: Test: Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant (1 x 5/500 mg); Reference: Dapagliflozin/metformin XR mg manufactured at Humacao plant (1 x 5/500 mg)</description>
        </group>
        <group group_id="P2">
          <title>Part 2</title>
          <description>Sequences 1, 2, 3 and 4 - each sequence had 10 subjects Part 2: EFGH, FEHG, EFHG, FEGH (E = test, fed; F = reference, fed; G = test, fasted; H = reference, fasted) Part 2: Test: Dapagliflozin/metformin XR manufactured at Mount Vernon plant (1 x 10/1000 mg); Reference: Dapagliflozin/metformin XR manufactured at Humacao plant (1 x 10/1000 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Positive drug screen at admission</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1</title>
          <description>Sequences 1, 2, 3 and 4- each sequence had 10 subjects; Part 1: ABCD, BADC, ABDC, BACD (A = test, fed; B = reference, fed; C = test, fasted; D = reference, fasted) Part 1: Test: Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant (1 x 5/500 mg); Reference: Dapagliflozin/metformin XR mg manufactured at Humacao plant (1 x 5/500 mg)</description>
        </group>
        <group group_id="B2">
          <title>Part 2</title>
          <description>Sequences 1, 2, 3 and 4 - each sequence had 10 subjects Part 2: EFGH, FEHG, EFHG, FEGH (E = test, fed; F = reference, fed; G = test, fasted; H = reference, fasted) Part 2: Test: Dapagliflozin/metformin XR manufactured at Mount Vernon plant (1 x 10/1000 mg); Reference: Dapagliflozin/metformin XR manufactured at Humacao plant (1 x 10/1000 mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="10.38"/>
                    <measurement group_id="B2" value="38.1" spread="9.71"/>
                    <measurement group_id="B3" value="36.5" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State</title>
        <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State</title>
          <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.3" spread="21.06"/>
                    <measurement group_id="O2" value="248.6" spread="20.79"/>
                    <measurement group_id="O3" value="251.6" spread="21.20"/>
                    <measurement group_id="O4" value="258.2" spread="18.35"/>
                    <measurement group_id="O5" value="471.9" spread="27.46"/>
                    <measurement group_id="O6" value="486.9" spread="26.47"/>
                    <measurement group_id="O7" value="504.4" spread="27.22"/>
                    <measurement group_id="O8" value="516.6" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5484" spread="24.69"/>
                    <measurement group_id="O2" value="5465" spread="27.87"/>
                    <measurement group_id="O3" value="4398" spread="29.41"/>
                    <measurement group_id="O4" value="4460" spread="29.69"/>
                    <measurement group_id="O5" value="8403" spread="27.90"/>
                    <measurement group_id="O6" value="8015" spread="31.65"/>
                    <measurement group_id="O7" value="7727" spread="30.82"/>
                    <measurement group_id="O8" value="7578" spread="35.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.</title>
        <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.</title>
          <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.1" spread="20.43"/>
                    <measurement group_id="O2" value="239.1" spread="21.10"/>
                    <measurement group_id="O3" value="243.4" spread="20.93"/>
                    <measurement group_id="O4" value="248.8" spread="17.92"/>
                    <measurement group_id="O5" value="454.7" spread="27.15"/>
                    <measurement group_id="O6" value="472.1" spread="26.72"/>
                    <measurement group_id="O7" value="490.9" spread="27.30"/>
                    <measurement group_id="O8" value="505.1" spread="26.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5307" spread="26.54"/>
                    <measurement group_id="O2" value="5205" spread="28.59"/>
                    <measurement group_id="O3" value="4211" spread="28.71"/>
                    <measurement group_id="O4" value="4212" spread="27.22"/>
                    <measurement group_id="O5" value="8040" spread="27.82"/>
                    <measurement group_id="O6" value="7798" spread="32.77"/>
                    <measurement group_id="O7" value="7456" spread="30.57"/>
                    <measurement group_id="O8" value="7401" spread="34.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of geometric means</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State</title>
        <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State</title>
          <description>To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.69" spread="26.42"/>
                    <measurement group_id="O2" value="41.33" spread="18.49"/>
                    <measurement group_id="O3" value="65.28" spread="25.49"/>
                    <measurement group_id="O4" value="67.41" spread="24.95"/>
                    <measurement group_id="O5" value="87.48" spread="30.14"/>
                    <measurement group_id="O6" value="90.14" spread="32.09"/>
                    <measurement group_id="O7" value="125.6" spread="30.77"/>
                    <measurement group_id="O8" value="132.7" spread="28.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510.2" spread="22.23"/>
                    <measurement group_id="O2" value="503.4" spread="22.16"/>
                    <measurement group_id="O3" value="563.2" spread="30.27"/>
                    <measurement group_id="O4" value="573.9" spread="28.55"/>
                    <measurement group_id="O5" value="982.6" spread="28.11"/>
                    <measurement group_id="O6" value="975.5" spread="27.89"/>
                    <measurement group_id="O7" value="1016" spread="35.36"/>
                    <measurement group_id="O8" value="998.5" spread="36.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dapagliflozin: Statistical Assessment of Bioequivalence for Dapagliflozin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment A and B.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 5/500 mg for Treatment C and D.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment E and F.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of geometric means</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Metformin: Statistical Assessment of Bioequivalence for Metformin following administration Dapagliflozin/Metformin XR 10/1000 mg for Treatment G and H.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% CIs for both dapagliflozin and metformin geometric mean ratio of AUC is entirely contained within an 80.00% to 125.00% interval, it will be concluded the 2 manufacturing sites are bioequivalent.</non_inferiority_desc>
            <param_type>Ratios of Geometric means</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (t Max)</title>
        <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (t Max)</title>
          <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="2.98"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.48" upper_limit="2.92"/>
                    <measurement group_id="O5" value="2.00" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.50" upper_limit="1.98"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.48" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="11.95"/>
                    <measurement group_id="O2" value="6.00" lower_limit="3.98" upper_limit="12.03"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="6.03"/>
                    <measurement group_id="O5" value="4.00" lower_limit="3.98" upper_limit="7.98"/>
                    <measurement group_id="O6" value="4.00" lower_limit="3.98" upper_limit="6.02"/>
                    <measurement group_id="O7" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="4.00" lower_limit="1.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]</title>
        <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]</title>
          <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>Hour (h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.01" spread="6.747"/>
                    <measurement group_id="O2" value="14.65" spread="7.245"/>
                    <measurement group_id="O3" value="13.73" spread="6.203"/>
                    <measurement group_id="O4" value="16.55" spread="8.260"/>
                    <measurement group_id="O5" value="14.88" spread="6.272"/>
                    <measurement group_id="O6" value="14.42" spread="5.778"/>
                    <measurement group_id="O7" value="14.72" spread="5.641"/>
                    <measurement group_id="O8" value="15.11" spread="5.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.48" spread="7.873"/>
                    <measurement group_id="O2" value="12.87" spread="6.587"/>
                    <measurement group_id="O3" value="11.91" spread="7.351"/>
                    <measurement group_id="O4" value="13.52" spread="8.760"/>
                    <measurement group_id="O5" value="14.18" spread="7.718"/>
                    <measurement group_id="O6" value="13.74" spread="6.984"/>
                    <measurement group_id="O7" value="14.38" spread="8.241"/>
                    <measurement group_id="O8" value="15.94" spread="9.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]</title>
        <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]</title>
          <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.3" spread="194.2"/>
                    <measurement group_id="O2" value="424.4" spread="217.3"/>
                    <measurement group_id="O3" value="412.7" spread="220.5"/>
                    <measurement group_id="O4" value="454.6" spread="202.6"/>
                    <measurement group_id="O5" value="476.5" spread="224"/>
                    <measurement group_id="O6" value="433.3" spread="196.1"/>
                    <measurement group_id="O7" value="441.7" spread="191.7"/>
                    <measurement group_id="O8" value="421.4" spread="163.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2030" spread="1407"/>
                    <measurement group_id="O2" value="2133" spread="1891"/>
                    <measurement group_id="O3" value="2104" spread="1309"/>
                    <measurement group_id="O4" value="2803" spread="2066"/>
                    <measurement group_id="O5" value="3357" spread="2549"/>
                    <measurement group_id="O6" value="3324" spread="2713"/>
                    <measurement group_id="O7" value="3635" spread="2648"/>
                    <measurement group_id="O8" value="3212" spread="2079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]</title>
        <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
        <time_frame>Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period</time_frame>
        <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
          <group group_id="O7">
            <title>Treatment G</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
          </group>
          <group group_id="O8">
            <title>Treatment H</title>
            <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]</title>
          <description>To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.</description>
          <population>PK Analysis Set: All subjects in the safety analysis set for whom at least one of the primary PK parameters could be calculated for at least one analyte (dapagliflozin or metformin), and who had no major protocol deviations thought to impact on analysis of the PK data.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.62" spread="4.617"/>
                    <measurement group_id="O2" value="20.55" spread="4.506"/>
                    <measurement group_id="O3" value="20.32" spread="4.503"/>
                    <measurement group_id="O4" value="19.68" spread="3.650"/>
                    <measurement group_id="O5" value="21.93" spread="5.747"/>
                    <measurement group_id="O6" value="21.22" spread="5.585"/>
                    <measurement group_id="O7" value="20.49" spread="5.138"/>
                    <measurement group_id="O8" value="20.00" spread="4.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.78" spread="22.71"/>
                    <measurement group_id="O2" value="94.89" spread="26.81"/>
                    <measurement group_id="O3" value="118.1" spread="32.16"/>
                    <measurement group_id="O4" value="116.9" spread="36.62"/>
                    <measurement group_id="O5" value="123.5" spread="34.68"/>
                    <measurement group_id="O6" value="130.5" spread="39.23"/>
                    <measurement group_id="O7" value="134.9" spread="37.59"/>
                    <measurement group_id="O8" value="140" spread="50.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening until 72 hours postdose for each treatment period (ie. visit 1 to visit 6).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Mount Vernon plant</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Fed - 5/500 mg - Dapagliflozin/metformin XR mg manufactured at Humacao plant</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>Fasted - 5/500 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
        </group>
        <group group_id="E5">
          <title>Treatment E</title>
          <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
        </group>
        <group group_id="E6">
          <title>Treatment F</title>
          <description>Fed - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
        </group>
        <group group_id="E7">
          <title>Treatment G</title>
          <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Mount Vernon plant</description>
        </group>
        <group group_id="E8">
          <title>Treatment H</title>
          <description>Fasted - 10/1000 mg - Dapagliflozin/metformin XR manufactured at Humacao plant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46 31 7761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

